Abstract: A root canal filling material for a tooth extraction or tooth non-extraction process can be used clinically because of its easy availability and can efficiently enhance dental tissue regeneration; a method for regenerating dental tissue using the filling material is also provided. A root canal filling material 200 including mesenchymal stem cells 220 excluding dental pulp stem cells, which are inserted into the apical side of a root canal subjected to pulp extirpation or to root canal enlargement and cleaning of an infected root canal and including an extracellular matrix 210 is provided, and a method for regenerating dental tissue, through a tooth extracting or tooth non-extracting process, including a step of injecting the root canal filling material into the apical side of a root canal of a non-extracted tooth subjected to pulp extirpation or to root canal enlargement and cleaning of an infected root canal is provided.

Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).

Abstract: Disclosed is a root canal filler for non-extracted tooth which causes no internal resorption or external resorption in a tooth with complete root formation, shows no odontoclast, and contributes to the regeneration of a dental tissue in which odontoblasts are smoothly aligned on the dentin wall. After pulpectomy or enlargement/cleaning of an infected root canal, a root canal filler for non-extracted tooth, which comprises tooth pulp stem cells and an extracellular matrix, is inserted into the apical side of the root canal of the non-extracted tooth. The tooth pulp stem cells may be, for example, dental pulp CXCR4-positive cells. It is preferred to attach, to the crown side of the root canal, migration factor(s) including at least one factor selected from among a cell migration factor, a cell proliferation factor, a neurotrophic factor and an angiogenic factor.

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A?1-42); APP672-709 (A?1-38)/APP672-713 (A?1-42); APP674-711 (A?3-40)/APP672-713 (A?1-42); APP672-710 (A?1-39)/APP672-713 (A?1-42); APP672-711 (A?1-40)/APP672-713 (A?1-42); and APP672-711 (OxA?1-40)/APP672-713 (A?1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC? who is negative for cerebral A? accumulation, an accumulation amount of cerebral A? of the test subject is determined as larger than an accumulation amount of cerebral A? of the person having normal cognitive function NC?.

Abstract: Provided is a pharmaceutical composition excellent in capability of an accelerated penetration into an affected area. The pharmaceutical composition capable of accelerated penetration into the affected area is formed by dispersing nano-bubbles, which are negatively charged and are given high internal pressures due to their surface tension, in the pharmaceutical composition in a form of a liquid or a gel including a predetermined drug.

Abstract: A method of treatment for pulpitis and/or enhancement for dentinogenesis, includes using dental materials that include at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein as an active ingredient. The dental materials can also contain a carrier having biocompatibility, and can contain at least one cell type among pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts.

Abstract: A dental ultrasonic drug delivery system capable of accurately cleaning the inside of root canals and killing bacteria in dentin tubules is provided. The dental ultrasonic drug delivery system delivers a drug to a target using an ultrasonic delivery device 800 . The drug is delivered in a mixed state with nanobubbles. A dental therapeutic probe for applying ultrasound is attached to the ultrasonic delivery device 800 . The dental therapeutic probe is selected from: (1) a root canal insertion probe 100 which is configured to be inserted into a root canal and causes ultrasound to propagate in the root canal; (2) a dental caries therapeutic probe which causes ultrasound to propagate in a dental caries portion; (3) a periodontal disease therapeutic probe which applies ultrasound to a periodontal disease portion; and (4) a hyperesthesia therapeutic probe which applies ultrasound to hyperesthesia portion.

Abstract: A method and an apparatus for measuring and displaying dental plaque are provided, and the method includes the steps of dividing near infrared light output from a light source into measurement light and reference light, applying the measurement light toward a tooth in an oral cavity and scanning the tooth with the measurement light, producing interference light from reflected light and back-scattered light from the tooth and the reference light, generating an optical coherence tomographic image based on a scattering intensity value of the interference light, extracting a dental plaque region having a specific scattering intensity value from the optical coherence tomographic image, and quantifying the dental plaque. A method and an apparatus for measuring and displaying gingiva and/or alveolar bone are further provided. A method and an apparatus for quantifying dental plaque, digitizing the dental plaque, and generating an image of the dental plaque are further provided.

Abstract: A material for treatment of cerebral infarction ameliorates angiopathy at a cerebral infarction region and improves brain function. The material for treatment of cerebral infarction according to the present invention comprises a dental pulp stem cell including at least one of a CD105-positive cell, an SP cell, a CD24-positive cell, a CD271-positive cell, and a CD150-positive cell. The material for treatment of cerebral infarction according to the present invention may contain a secretory protein of the dental pulp stem cell. Transplanted dental pulp stem cells do not directly differentiate into neural progenitor cells or neural cells and indirectly participate in the promotion of differentiation to restore and cure a cerebral infarction region such that the region becomes normal.

Abstract: A suction drain device of a disclosed liquid collecting apparatus actively pushes and pulls blood. This achieves liquid collection at high speed even under decreased pressure depending on a physiological state of an animal. Moreover, the liquid collecting apparatus includes a First flow path and a second flow path having a given length. Accordingly, the flow path with a given length set in advance and thus a known volume allows collection of a given amount volume of blood without measuring a length and an amount of blood using a volume measuring device. Accordingly, no need of the measuring device allows reduction in size of the liquid collecting apparatus. Consequently, the liquid collecting apparatus can be installed adjacent to the animal to achieve reduction in dead volume. Moreover, blood is flown to a fourth flow path branched with a connecting terminal, and is also flown to the second flow path branched with a connecting terminal.

Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.

Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.

Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.

Abstract: A membrane separation culture device includes an upper structure including a vessel in which at least a portion of the bottom thereof is formed with a separation membrane having pores that allow stem cells to permeate therethrough, and a lower structure including a vessel that retains a fluid in which the membrane of the upper structure is immersed.

Abstract: Disclosed is a root canal filler for non-extracted tooth which causes no internal resorption or external resorption in a tooth with complete root formation, shows no odontoclast, and contributes to the regeneration of a dental tissue in which odontoblasts are smoothly aligned on the dentin wall. After pulpectomy or enlargement/cleaning of an infected root canal, a root canal filler for non-extracted tooth, which comprises tooth pulp stem cells and an extracellular matrix, is inserted into the apical side of the root canal of the non-extracted tooth. The tooth pulp stem cells may be, for example, dental pulp CXCR4-positive cells. It is preferred to attach, to the crown side of the root canal, migration factor(s) including at least one factor selected from among a cell migration factor, a cell proliferation factor, a neurotrophic factor and an angiogenic factor.

Abstract: A material for treatment of cerebral infarction ameliorates angiopathy at a cerebral infarction region and improves brain function. The material for treatment of cerebral infarction according to the present invention comprises a dental pulp stem cell including at least one of a CD105-positive cell, an SP cell, a CD24-positive cell, a CD271-positive cell, and a CD150-positive cell. The material for treatment of cerebral infarction according to the present invention may contain a secretory protein of the dental pulp stem cell. Transplanted dental pulp stem cells do not directly differentiate into neural progenitor cells or neural cells and indirectly participate in the promotion of differentiation to restore and cure a cerebral infarction region such that the region becomes normal.

Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.

Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.

Abstract: A dental ultrasonic drug delivery system capable of accurately cleaning the inside of root canals and killing bacteria in dentin tubules is provided. The dental ultrasonic drug delivery system delivers a drug to a target using an ultrasonic delivery device 800. The drug is delivered in a mixed state with nanobubbles. A dental therapeutic probe for applying ultrasound is attached to the ultrasonic delivery device 800. The dental therapeutic probe is selected from: (1) a root canal insertion probe 100 which is configured to be inserted into a root canal and causes ultrasound to propagate in the root canal; (2) a dental caries therapeutic probe which causes ultrasound to propagate in a dental caries portion; (3) a periodontal disease therapeutic probe which applies ultrasound to a periodontal disease portion; and (4) a hyperesthesia therapeutic probe which applies ultrasound to hyperesthesia portion.

Abstract: Disclosed is a root canal filler for non-extracted tooth which causes no internal resorption or external resorption in a tooth with complete root formation, shows no odontoclast, and contributes to the regeneration of a dental tissue in which odontoblasts are smoothly aligned on the dentin wall. After pulpectomy or enlargement/cleaning of an infected root canal, a root canal filler for non-extracted tooth, which comprises tooth pulp stem cells and an extracellular matrix, is inserted into the apical side of the root canal of the non-extracted tooth. The tooth pulp stem cells may be, for example, dental pulp CXCR4-positive cells. It is preferred to attach, to the crown side of the root canal, migration factor(s) including at least one factor selected from among a cell migration factor, a cell proliferation factor, a neurotrophic factor and an angiogenic factor.